Forxiga CKD Japan Post-Marketing Surveillance (PMS)

Trial Identifier: D169AC00007
Sponsor: AstraZeneca
NCTID:: NCT05306210
Start Date: April 2022
Primary Completion Date: April 2025
Study Completion Date: April 2025
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan
Japan Akita, Japan
Japan Aomori, Japan
Japan Chiba, Japan
Japan Ehime, Japan
Japan Fukui, Japan
Japan Fukuoka, Japan
Japan Fukushima, Japan
Japan Gifu, Japan
Japan Gunma, Japan
Japan Hiroshima, Japan
Japan Hokkaido, Japan
Japan Hyogo, Japan
Japan Ibaraki, Japan
Japan Ishikawa, Japan
Japan Iwate, Japan
Japan Kagawa, Japan
Japan Kagoshima, Japan
Japan Kanagawa, Japan
Japan Kochi, Japan
Japan Kumamoto, Japan
Japan Kyoto, Japan
Japan Mie, Japan
Japan Miyagi, Japan
Japan Miyazaki, Japan
Japan Nagano, Japan
Japan Nagasaki, Japan
Japan Nara, Japan
Japan Niigata, Japan
Japan Oita, Japan
Japan Okayama, Japan
Japan Okinawa, Japan
Japan Osaka, Japan
Japan Saga, Japan
Japan Saitama, Japan
Japan Shiga, Japan
Japan Shimane, Japan
Japan Shizuoka, Japan
Japan Tochigi, Japan
Japan Tokushima, Japan
Japan Tokyo, Japan
Japan Toyama, Japan
Japan Wakayama, Japan
Japan Yamagata, Japan
Japan Yamaguchi, Japan
Japan Yamanashi, Japan